• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Quris-AI Acquires Nortis to Enhance Bio-AI Platform and Advance Drug Safety Prediction

by Fred Pennic 10/29/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Quris-AI, a leading Bio-AI company revolutionizing drug development, has acquired Nortis, a pioneer in microphysiology systems (MPS) technology, formerly known as Numa Biosciences. 

– The strategic acquisition will integrate Nortis’s advanced Kidney-on-Chip technology into Quris-AI’s Bio-AI platform, enhancing its ability to predict drug safety and efficacy in humans.

Combining Cutting-Edge Technologies

Nortis’s Kidney-on-Chip models have been validated by the National Center for Advancing Translational Sciences (NCATS) and represent a significant advancement in in-vitro drug testing and personalized medicine. By combining this technology with Quris-AI’s machine learning models and patented patient-on-chip system, the company aims to improve the accuracy and efficiency of drug development.

Quris-AI’s Bio-AI Platform: Revolutionizing Drug Development

Quris-AI’s Bio-AI Clinical Prediction Platform is transforming the drug development process by simulating clinical trials and predicting drug responses in humans. This approach reduces the reliance on traditional animal testing and accelerates the identification of promising drug candidates.

The acquisition of Nortis will enable Quris-AI to:

  • Enhance its Bio-AI Platform: Integrate Nortis’s Kidney-on-Chip technology to improve the accuracy of drug safety and efficacy predictions.
  • Advance Drug Development: Accelerate the development of new drugs by identifying and eliminating potentially harmful candidates earlier in the process.
  • Expand Research Collaborations: Continue Nortis’s collaborations with research institutes, the FDA, and pharmaceutical companies to advance kidney disease research.
  • Improve Drug Safety Prediction: Strengthen Quris-AI’s capabilities in predicting drug safety and efficacy in humans.

“We are thrilled to incorporate Nortis’s pioneering technology into the Quris-AI platform,” said Dr. Isaac Bentwich, Founder and CEO of Quris-AI. “This acquisition represents a powerful synergy between Nortis’s legacy of scientific excellence and Quris’s cutting-edge Bio-AI capabilities to significantly enhance the accuracy of drug safety predictions in both pre-clinical and clinical phases. We are dedicated to continuing to push the boundaries of drug safety prediction and personalized medicine, ultimately leading to better patient outcomes and advancing the future of healthcare.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Healthcare Mergers & Acquisitions

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

Advancing Diabetes Care: Combating Burnout and Harnessing Technology

White House Event Unveils CMS Health Tech Ecosystem Initiative

White House Event Unveils CMS Health Tech Ecosystem Initiative

Meaningful Use Penalties_Meaningful Use_Partial Code Free_Senators Urge CMS to Establish Clear Metrics for ICD-10 Testing

CMS Finalizes TEAM Model: A New Era of Value-Based Surgical Care

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

HHS Finalizes HTI-4 Rule: Prior Authorization & E-Prescribing Interoperability

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low, But AI Dominates and $1B+ IPOs Emerge

Healthcare Investment Shifts in 1H 2025: AI Remains a Bright Spot Amidst Fundraising Decline

Digital Health Faces Q2'25 Pullback: Funding Falls to 5-Year Low

Digital Health Faces Q2’25 Pullback: Funding Falls to 5-Year Low

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |